Rituximab maintenance in indolent lymphoma: indications and controversies.
Over the past few years it has been shown in previously untreated and relapsed/refractory follicular lymphoma that rituximab maintenance has a clear clinical benefit after induction with rituximab plus chemotherapy, chemotherapy alone, or rituximab monotherapy. However, the optimal dose, schedule, and duration of rituximab maintenance therapy still need to be established. The important issue of maintenance treatment versus retreatment upon relapse is the topic of the ongoing large randomized phase III Rituximab Extended Schedule or Retreatment Trial (RESORT). Current data indicate that rituximab maintenance can be safely administered for up to 2 years, although assessment of long-term safety requires longer follow-up.
van Oers
Marinus H J
MH
Department of Hematology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. M.H.vanOers@AMC.UVA.NL
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab
J Clin Oncol. 1998 Apr;16(4):1538-46
9580385
Br J Cancer. 2001 Jul 6;85(1):29-35
11437398
J Clin Oncol. 1995 Jul;13(7):1726-33
7602362
Blood. 2005 Feb 15;105(4):1417-23
15494430
J Clin Oncol. 2000 May;18(10 ):2010-6
10811664
Blood. 2004 Jun 15;103(12):4416-23
14976046
J Clin Oncol. 2005 Feb 20;23(6):1096-102
15657402
Cancer. 1987 Jul 15;60(2):156-60
3297278
Clin Cancer Res. 1999 Mar;5(3):611-5
10100713
Ann Oncol. 1998 Sep;9(9):995-1001
9818074
Blood. 2006 Dec 15;108(13):4003-8
16946304
J Clin Oncol. 1998 Jan;16(1):41-7
9440721
J Clin Oncol. 2005 Apr 1;23 (10 ):2215-23
15684317
Blood. 2005 Dec 1;106(12):3725-32
16123223
J Clin Oncol. 2005 Feb 20;23(6):1088-95
15657401
J Clin Oncol. 2002 Oct 15;20(20):4261-7
12377971
J Clin Oncol. 1995 Jan;13(1):140-7
7799014
Leuk Lymphoma. 1996 Feb;20(5-6):495-9
8833409
Blood. 2004 Nov 15;104(10):3064-71
15284112
Clin Oncol (R Coll Radiol). 2006 Mar;18(2):155-6
16523821
Br J Haematol. 1999 Aug;106(2):571-2
10460626
Cancer Treat Rev. 2005 Oct;31(6):456-73
16054760
Blood. 2006 Nov 15;108(10):3295-301
16873669
Cancer. 1988 Feb 1;61(3):441-7
3338014
Ann Oncol. 2000;11 Suppl 1:123-6
10707793
J Clin Oncol. 1998 Aug;16(8):2825-33
9704735